InVivo enters new partnership to study spinal scaffold & stem cell combination: 3 notes

Shayna Korol -   Print  |

InVivo Therapeutics entered into a joint research agreement with Q Therapeutics to evaluate the safety and feasibility of combining InVivo's Neuro-Spinal Scaffold with stem cells.

Here are three things to know:

1. The scaffold will be combined with Q Therapeutics' adult neural progenitor cells, including those from induced pluripotent stem cells for central nervous system applications.

2. InVivo is a biotechnology company focused on treating spinal cord injuries.

3. Q Therapeutics develops adult neural progenitor cell therapies for CNS disease and injury treatment.

InVivo's President and CEO Richard Toselli, MD, said, "Although InVivo remains very focused on and optimistic about the potential clinical benefit of the Neuro-Spinal Scaffold as a standalone technology, we believe this scientific partnership will allow both parties the opportunity to evaluate in parallel whether there is also a potential additive preclinical benefit of the combined technologies."

More articles on biologics:
Bioventus selects Pfizer as exclusive distribution partner for hip, knee OA solution in Brazil: 3 notes
Orthobiologics company completes 250 cases with OsteoCrete magnesium-based bone void filler: 3 notes
Maryland Stem Cell Research Fund awards 1st round of $8.2M funding initiative: 5 things to know

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers